New Daily Medication Significantly Extends Life for Pancreatic Cancer Sufferers

A groundbreaking new oral medication has been shown to nearly double the survival duration for patients with advanced pancreatic cancer, prompting medical experts to hail the trial results as a transformative moment in oncology. The drug, identified as daraxonrasib, represents a major advance in treating a malignancy that carries the highest fatality rate among all significant cancers. It functions by targeting and deactivating the mutated KRAS gene, a genetic driver present in over 90% of pancreatic tumors that fuels cancer progression.

The comprehensive clinical study, which enrolled 500 participants across North America, Europe, and Asia, revealed striking differences in outcomes. Patients receiving standard chemotherapy had an average survival period of 6.6 months, whereas those treated with daraxonrasib survived an average of 13.2 months. Additionally, the new treatment was associated with a reduced burden of adverse reactions.

"These results are landscape-changing for metastatic pancreatic cancer patients with a KRAS mutation," stated Rachna Shroff, who leads the hematology/oncology division at the University of Arizona Cancer Centre.

Pancreatic cancer is frequently diagnosed at a late stage and remains notoriously challenging to treat effectively. Statistics from Cancer Research UK indicate that more than 50% of individuals succumb to the disease within three months of receiving a diagnosis. In Britain alone, there are approximately 11,500 new cases annually, resulting in around 10,200 deaths. The high-profile case of actor Alan Rickman, who passed away in 2016 just five months after his diagnosis, highlights the aggressive nature of the illness.

Early detection is complicated because symptoms often do not manifest until later stages and can mimic other less serious conditions. Potential indicators include jaundice, persistent itching, darker urine, paler stools, unexplained weight loss, fatigue, and elevated body temperature.

The trial, conducted by American researchers and presented at the annual meeting of the American Society of Clinical Oncology in Chicago, involved 248 patients administered daraxonrasib and 252 who received chemotherapy. The majority of participants had tumors featuring specific KRAS gene mutations. Beyond the significant extension of life, the once-daily pill demonstrated a better safety profile than chemotherapy. Severe side effects were reported in 43.6% of patients on daraxonrasib, compared to 57.5% of those on chemotherapy.

Anna Jewell, director of services, research, and innovation at Pancreatic Cancer UK, described the findings as "some of the most exciting developments we have seen in pancreatic cancer for a very long time." She emphasized the human impact of the data, noting, "More time with those we love most is truly priceless. We must do everything possible to ensure the most promising new treatments are available here in the UK."

Source: BBC News Generated at: 2026-06-01 02:50:00 UTC